Mogamulizumab-kpkc - Indications, Dosage, Side Effects and Precautions

Mogamulizumab-kpkc Medication Information

Get detailed information on Mogamulizumab-kpkc, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it.

The updated prescription information on Mogamulizumab-kpkc provides an overview of possible side effects, precautions, warnings, and storage tips.

You'll also find brand names used in india and internationally, along with pricing details. For further clarification, consult your healthcare provider.

Generic Name : Mogamulizumab-kpkc Pronunciation : moe-GAM-ue-LIZ-ue-mab-kpkc Therapeutic Classification : Monoclonal antibodies

Trade Names/Brand Names of Mogamulizumab-kpkc

India :

Poteligeo

Why is Mogamulizumab-kpkc Prescribed? (Indications)

Mogamulizumab-kpkc is used to treat mycosis fungoides or Sézary syndrome in adult patients whose disease condition returns after treatment with at least one prescribed chemotherapy regimen.

Mogamulizumab-kpkc is a human monoclonal antibody that binds to CC chemokine receptor 4 (CCR4), a specific protein found on certain cancer cells.

Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common but hard to treat subtypes of cutaneous T-cell lymphoma (CTCL). In these diseases, the T-cells (a type of white blood cell) become cancerous and mainly affect the skin resulting in itchy red rashes and several kinds of skin lesions.

When should Mogamulizumab-kpkc not be taken? (Contraindications)

Mogamulizumab-kpkc should not be used in patients with-

• Allergic to mogamulizumab-kpkc
• History of skin disorders
• Pregnancy
• Children under 18 years

Caution is required when giving to patients who are-

• Breastfeeding
• With a history of autoimmune disease (Immune system attacks own cells by mistake)
• Weak immunity

What is the dosage of Mogamulizumab-kpkc?

• The recommended dose of mogamulizumab-kpkc is 1 mg/kg body weight given slowly for at least 1-hour duration in patients who never show any disease progression or when the treatment with the drug does not result in intolerable toxicity.

• The dose of mogamulizumab-kpkc and the required number of vials needed to prepare the infusion must be calculated based on the individual body weight.

• The dose of mogamulizumab-kpkc can be reduced or modified according to the occurrence of side effects. The infusion rate of mogamulizumab-kpkc should be reduced by a minimum of 50 % when the treatment is started again after the side effects are under control.

• The treatment with mogamulizumab-kpkc can either be temporarily stopped or permanently discontinued based on the severity of the side effects, and the patients must be treated appropriately to reduce the impact caused by the side effects.

How should Mogamulizumab-kpkc be taken?

• Mogamulizumab-kpkc is available as an injectable emulsion that should be given directly into the vein as a very slow infusion for at least 1 hour.

• Mogamulizumab-kpkc should be given on day one followed by days 8, 15, 22 of the first 28-day cycle. After the first cycle it is given on days 1 and 15 (twice in a 28-day cycle).

• The dose of mogamulizumab-kpkc can be given within two days of the scheduled dose. Suppose a dose is missed, the next dose of mogamulizumab-kpkc can be given immediately and then followed with the next scheduled dose.

• It is dangerous to give mogamulizumab-kpkc just under the skin (subcutaneous) or as a fast injection into the deep vein (intravenous or IV) and therefore should be avoided.

• Patients can be given anti-allergic drugs and fever-reducing medications during subsequent infusions of mogamulizumab-kpkc if any side effect occurred when it was given the first time.

• The contents of mogamulizumab-kpkc should be transferred into an intravenous bag containing 0.9% sodium chloride to arrive at a final concentration of 1 mg/ ml to 3.0 mg/ ml.

• Gently invert the intravenous bag containing the diluted solution to ensure proper mixing without shaking.

• Do not mix mogamulizumab-kpkc with other drugs and always give mogamulizumab-kpkc through a separate IV line to avoid reactions between drugs.

What are the side effects of Mogamulizumab-kpkc?

Gastrointestinal: Loose stools, nausea, constipation, mouth ulcer, decreased appetite, vomiting, stomach pain
Nervous system: Headache, difficulty in sleeping, dizziness, burning sensation and numbness of hands and feet, depression
Blood: High blood pressure, fluid accumulation, heart rate abnormalities, low levels of hemoglobin and platelets
Skin: Rashes, dermatitis, skin eruption, red skin, dry or rough skin, hair loss
Musculoskeletal: Neck pain, muscle pain, back pain, bone pain, pain in the hands or feet
Others: Cough, infections of the airways, fever, abnormal levels of blood sugar, magnesium, calcium, uric acid, white blood cells, and phosphate

What are the other precautions for Mogamulizumab-kpkc?

• Check the solution properly before giving to the patient. If any particulate matter or discoloration is seen it should be discarded immediately.

• Patients must be advised to inform the health care provider immediately if any unusual or intolerable side effects occur during the treatment with mogamulizumab-kpkc.

What are the Drug Interactions of Mogamulizumab-kpkc?

The doctor should be informed by the patient before prescribing mogamulizumab-kpkc, about any prescription, Over-The-Counter drugs, or herbal supplements they are taking, to avoid dangerous drug side effects.

What are the storage conditions for Mogamulizumab-kpkc?

• Store mogamulizumab-kpkc vials in cold storage, or in a refrigerator between 2°C and 8°C.

• The diluted solution of mogamulizumab-kpk can be stored in a refrigerator between 2°C and 8°C but should be used within 4 hours.

• Any unused solution stored or unused after 4 hours must be discarded.

• Avoid shaking the mogamulizumab-kpkc solution or keeping it in a freezer.